EUVIMEDEUVIMED entdecken
Crossref

Reliability of Ki67‐Labeling Index in Core Needle Biopsy Specimens of ER+/HER2− Breast Cancers

Yumi Fukaya, Makoto Wakahara, Keiko Hosoya, Naoko Nouchi, Yoshihisa Umekita

Pathology International · 2025

DOI: 10.1111/pin.70005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology International, 2025. Verfasst von Yumi Fukaya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of General Thoracic Surgery and Breast and Endocrine Surgery, Yonago, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Ki-67 Antigen. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The reliability of Ki67‐labeling index (LI) in core needle biopsy (CNB) of ER+/HER2− invasive breast carcinoma (IBC) and factors affecting the discordance of Ki67‐LI between CNB and surgical resection (SR) remain unsolved. We aimed to elucidate factors influencing the discordance of Ki67‐LI between CNB and SR to classify ER+/HER2− IBC into luminal A‐like (LumA) and luminal B‐like (LumB). The cohort included 326 ER+/HER2− IBCs available with Ki67‐LI data at both CNB and SR specimens. Survival analysis was performed on 122 patients. Spearman's rank correlation coefficient of Ki67‐LI between them was 0.683. The log‐rank test showed that patients with ER+/HER2− IBC with ≥ 20% Ki67‐LI at CNB ( p < 0.001) and SR specimens ( p < 0.001) had significantly shorter disease‐free survival. In multivariate analysis, a negative PgR ( p = 0.002) and > 2 cm pathological tumor size ( p < 0.001) had the most significant effect on the discordance of Ki67‐LI between CNB and SR at 20% and 30% cutoffs, respectively. Histological grade III had a significant effect on the concordance between them ( p = 0.01) at 20% cutoff. Ki67‐LI assessment in CNB may be useful for classifying ER+/HER2− IBC into LumA and LumB with caution of some prognostic factors and cutoffs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsKi-67 AntigenHumansFemaleBiopsy, Large-Core NeedleMiddle AgedErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenAgedAdultBiomarkers, TumorReproducibility of ResultsPrognosisDisease-Free SurvivalAged, 80 and over

Stichwörter der Autor:innen

Ki67breast cancercore needle biopsylumina‐like

Substanzen

Ki-67 AntigenErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenBiomarkers, TumorERBB2 protein, humanMKI67 protein, human

Autor:innen und Institutionen

  • Department of Surgery, Division of General Thoracic Surgery and Breast and Endocrine Surgery, Yonago, Japan.
  • Department of Pathology, Faculty of Medicine, Tottori University, Tottori, Japan.

Zitieren

APA

Fukaya, Y., Wakahara, M., Hosoya, K., Nouchi, N., & Umekita, Y. (2025). Reliability of Ki67‐Labeling Index in Core Needle Biopsy Specimens of ER+/HER2− Breast Cancers. Pathology International. https://doi.org/10.1111/pin.70005

Vancouver

Fukaya Y, Wakahara M, Hosoya K, Nouchi N, Umekita Y. Reliability of Ki67‐Labeling Index in Core Needle Biopsy Specimens of ER+/HER2− Breast Cancers. Pathology International. 2025. doi:10.1111/pin.70005

BibTeX
@article{Fukaya2025,
  author = {Fukaya, Yumi and Wakahara, Makoto and Hosoya, Keiko and Nouchi, Naoko and Umekita, Yoshihisa},
  title = {Reliability of Ki67‐Labeling Index in Core Needle Biopsy Specimens of ER+/HER2− Breast Cancers},
  journal = {Pathology International},
  year = {2025},
  doi = {10.1111/pin.70005}
}
Kostenlos starten →